ConductScience.org, home

Trial · NCT02674412

Buspirone for Functional Dysphagia

NCT02674412, Not applicable, Completed, The Cleveland Clinic; results first posted 2018-08-10

3 sourcestrials-2026-11-12-0.5.0

Download JSON
Cite this record

ConductScience Library. Buspirone for Functional Dysphagia. Trials, record NCT02674412. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02674412

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title
Buspirone for Functional Dysphagia
NCT number
NCT02674412
Status
Completed
Phases
Not applicable
Enrollment
10 participants, actual
Lead sponsor
The Cleveland Clinic
Conditions
Functional Dysphagia, Ineffective Esophageal Motility
Interventions
Buspirone, Placebo
First posted
2016-02-04
Last updated
2018-08-10
Results first posted
2018-08-10

Source ClinicalTrials.gov

Registered outcomes3

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

ListOutcomeTime frameDescription
PrimaryChange in Distal Contractile Index (DCI) on High Resolution Esophageal ManometryChange in the score from Baseline to 14 daysDCI is a measure of the strength of muscle contractions in the esophagus while swallowing. It is measured in mm Hg, and values greater than 450mm Hg are considered Normal.
SecondaryChange in Gastroesophageal Reflux Disease - Health Related Quality Questionnaire ScoreChange in the score from Baseline to 14 daysA 16-question questionnaire with a score range from 0 to 80, with higher scores indicating worse outcomes (more severe symptoms of GERD).
SecondaryChange in Percentage of Normal Swallows Recorded in a Series of 10 Measured Swallows.14 daysA normal swallow is defined as a swallow with a Distal Contractile Index greater than 450mm Hg

Outcomes3

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

TypeOutcomeTime framePopulationUnitsMeasured as
PRIMARYChange in Distal Contractile Index (DCI) on High Resolution Esophageal ManometryChange in the score from Baseline to 14 daysmm HgMEAN
SECONDARYChange in Gastroesophageal Reflux Disease - Health Related Quality Questionnaire ScoreChange in the score from Baseline to 14 daysScores on a scaleMEAN
SECONDARYChange in Percentage of Normal Swallows Recorded in a Series of 10 Measured Swallows.14 dayspercentage of swallowsMEAN

Results by group6

Each measurement the trial posted, group by group, in the words and numbers it posted.

OutcomeGroupCategoryValueSpreadUnits
Change in Distal Contractile Index (DCI) on High Resolution Esophageal ManometryBuspirone241.9Standard Deviation 771.7mm Hg
Change in Distal Contractile Index (DCI) on High Resolution Esophageal ManometryPlacebo340.4Standard Deviation 761.7mm Hg
Change in Gastroesophageal Reflux Disease - Health Related Quality Questionnaire ScoreBuspirone-4.1Standard Deviation 22.2Scores on a scale
Change in Gastroesophageal Reflux Disease - Health Related Quality Questionnaire ScorePlacebo-10.2Standard Deviation 16.6Scores on a scale
Change in Percentage of Normal Swallows Recorded in a Series of 10 Measured Swallows.Buspirone15Standard Deviation 37percentage of swallows
Change in Percentage of Normal Swallows Recorded in a Series of 10 Measured Swallows.Placebo20Standard Deviation 39percentage of swallows

Participant flow6

How many started, completed or left each group, period by period.

PeriodMilestoneGroupParticipantsUnits counted
Overall StudySTARTEDBuspirone Then Placebo5
Overall StudySTARTEDPlacebo Then Buspirone5
Overall StudyCOMPLETEDBuspirone Then Placebo5
Overall StudyCOMPLETEDPlacebo Then Buspirone5
Overall StudyNOT COMPLETEDBuspirone Then Placebo0
Overall StudyNOT COMPLETEDPlacebo Then Buspirone0

Adverse events0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

None in this release.

Adverse event totals6

The totals the trial posted for each group.

TotalGroupAffectedAt risk
Total, all-cause mortalityBuspirone010
Total, all-cause mortalityPlacebo010
Total, other adverse eventsBuspirone010
Total, other adverse eventsPlacebo010
Total, serious adverse eventsBuspirone010
Total, serious adverse eventsPlacebo010

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons2

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

ComparisonSource
Buspirone vs Placebo: deaths from any causeTrial comparisons
Buspirone vs Placebo: serious adverse eventsTrial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov
2026-11-12
ClinicalTrials.gov
Results, from AACT
2026-03-23
AACT
NIH grant links
2026-11-13
NIH RePORTER

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02674412

GET https://conductscience.org/api/trials/v1/NCT02674412/registered